Recent news and posts
Two projects awarded under the 2022 "Subsidy scheme for promising care" in the Netherlands
In April 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects which were awarded a total amount of €9.4 million under round 5 of the subsidy scheme for Promising care in 2022:
- Transcatheter tricuspid valve repair in patients with severe leakage of the tricuspid valve in the heart (TRACE-NL);
- Precision radiation in patients with epilepsy (PRECISION study).
The study of transcatheter tricuspid valve repair in patients with severe leakage of the tricuspid valve (TRACE-NL) was awarded a subsidy of €7.1 million within the framework of the "Subsidy scheme for promising care". The project started on May 1, 2022. It will be supervised by the Sint Antonius Hospital (Nieuwegein) and will last for six years. After completing the project, the research results will be submitted to the ZIN around May 2028 for the decision about inclusion in the Basic Health Insurance. The publication of the ZIN position on reimbursement under the Basic Insurance Package is scheduled for November 2029.
A multicenter randomized controlled trial of precision irradiation in adult patients with medication-resistant, localized epilepsy who are not eligible for surgery (PRECISION study) was awarded a subsidy of €2.3 million within the framework of the "Subsidy scheme for promising care". The project led by Maastricht Radiation Oncology (Maastro) will start on September 1, 2022, and last for six years. After completing the project, the research results will be submitted to the ZIN around September 2028 for the decision about inclusion in the Basic Health Insurance. The publication of the ZIN position on reimbursement under the Basic Insurance Package is scheduled for March 2029.
Based on the scientific evidence, the ZIN will take a position after the end of the research process to determine whether these procedures comply with the criteria of "science and practice". The treatment will be reimbursed under Basic Health Insurance if the effectiveness and safety are proven.
The full details in Dutch can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).